[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pluto Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100622971",false,"NCT07390552","A Study of PLH-2301 in Subjects With Sarcopenia","A Prospective, Randomized, Double-blinded, Placebo-controlled, 4-Parallel Arm, Multi-center, Phase 2 Trial to Evaluate Efficacy and Safety of Orally Administered PLH-2301 in Elderly Patients With Sarcopenia","PLH-2301_P2","Inclusion Criteria:\n\n* Male or female subjects aged 65 years or older at the time of consent\n* Diagnosis of sarcopenia based on predefined diagnostic criteria\n* Short Physical Performance Battery (SPPB) total score within the protocol-defined range at screening\n* Stable body weight for at least 3 months prior to screening\n* Able to walk independently with or without assistive devices\n* Willing and able to comply with study procedures\n* Provided written informed consent prior to any study-specific procedures\n\nExclusion Criteria:\n\n* History of clinically significant neuromuscular or musculoskeletal disorders that could affect muscle function\n* Uncontrolled cardiovascular, hepatic, renal, or metabolic disease\n* Use of medications known to affect muscle mass or function within the protocol-defined washout period\n* Participation in another interventional clinical trial within 3 months prior to screening\n* Any medical or psychiatric condition that, in the investigator's opinion, would interfere with study participation","ALL","65 Years",{"count":19,"type":20},168,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia.\n\nEligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks.\n\nThe primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.",[26],"Sarcopenia in Elderly",[28],"Sarcopenia","RECRUITING","2026-05-10",{"date":32,"type":33},"2026-05-12","ACTUAL",{"date":35,"type":33},"2026-05-08",{"date":37,"type":20},"2027-06-30",{"name":39,"class":40},"Pluto Inc.","INDUSTRY",5,""]